Background: Radiolabeled prostate-specific membrane antigen PSMA-based PET/CT or
PET/MRI is a whole-body imaging technique currently performed for the detection of prostate cancer
lesions. PSMA has been also demonstrated to be expressed by the neovasculature of many other solid
Objective: The aim of this review is to evaluate the possible diagnostic role of radiolabeled PSMA
PET/CT or PET/MRI in patients with gliomas and glioblastomas, by summarizing the available literature
Methods: A comprehensive literature search of the PubMed/MEDLINE, Scopus, Embase and Cochrane
library databases was conducted to find relevant published articles about the diagnostic performance
of radiolabeled PSMA binding agents in PET/CT or PET/MRI imaging of patients with suspected
gliomas or glioblastomas.
Results: Seven case reports or case series and 3 studies enrolling more than 10 patients showed that
gliomas and glioblastoma are PSMA-avid tumors.
Conclusion: Radiolabeled PSMA imaging seems to be useful in analyzing glioma/glioblastoma. Further
studies enrolling a wider population are needed to clarify the real clinical and diagnostic role of
radiolabeled PSMA in this setting and its possible position in the diagnostic flow-chart.